Newly appointed Chairman of the Board of Vicore Pharma Holding (ticker: VICO), Leif Darner has acquired 100,000 shares from Protem Wessman AB, controlled by Göran Wessman, former Chairman of the Board and now Board member of Vicore Pharma Holding. The deal has taken place outside the stock exchange.
“The deal reflects Leif Darner's confidence in the company and his extended engagement as Chairman of the Board”, says Göran Wessman.
For further information, please contact:
Göran Wessman, Board member
Tel: 0708-16 14 50 or e-mail: firstname.lastname@example.org
Leif Darner, Chairman of the Board
Tel: 0705-79 04 62 or e-mail: email@example.com
About Vicore Pharma Holding
Vicore Pharma, a Nasdaq Stockholm First North listed holding-, and management company. Vicore Pharma develops drugs targeting stimulation of the AT2 Receptor (AT2R) in the Renin-Angiotensin-System (RAS). The company vision is to establish AT2-agonists as a new effective class of small molecule drugs. Our lead candidate, C21 will be focused on the indication Idiopatic pulmonary fibrosis (IPF). For further information, please refer to www.vicorepharma.com
This is information which Vicore Pharma Holding AB is required to disclose under the EU Market Abuse Regulation and the Securities Market Act. The information was provided by the above contact person's auspices, for publication May 17, 2017 at. 14:15 CET.
Vicore Pharmas share is listed on NASDAQ Stockholm, First North under the ticker VICO.
The company´s Certified Adviser is Redeye AB.
Vicore Pharmas affärsstrategi är att leda utvecklingen av nya molekyler med agonistisk verkan på AT2 receptorn för att utveckla framgångsrika läkemedel.